Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RAPT Therapeutics, Inc. (RAPT) Current Deferred Revenue (2020 - 2022)

RAPT Therapeutics' Current Deferred Revenue history spans 3 years, with the latest figure at $645000.0 for Q1 2022.

  • For Q1 2022, Current Deferred Revenue fell 79.43% year-over-year to $645000.0; the TTM value through Mar 2022 reached $645000.0, down 79.43%, while the annual FY2021 figure was $1.0 million, 75.2% down from the prior year.
  • Current Deferred Revenue for Q1 2022 was $645000.0 at RAPT Therapeutics, down from $1.0 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $6.0 million in Q2 2020 and bottomed at $645000.0 in Q1 2022.
  • The 3-year median for Current Deferred Revenue is $3.1 million (2021), against an average of $3.3 million.
  • The largest annual shift saw Current Deferred Revenue tumbled 45.62% in 2021 before it tumbled 79.43% in 2022.
  • A 3-year view of Current Deferred Revenue shows it stood at $4.1 million in 2020, then plummeted by 75.2% to $1.0 million in 2021, then tumbled by 36.52% to $645000.0 in 2022.
  • Per Business Quant, the three most recent readings for RAPT's Current Deferred Revenue are $645000.0 (Q1 2022), $1.0 million (Q4 2021), and $1.5 million (Q3 2021).